A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion, 0.5%, for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) Form of Cutaneous T-Cell Lymphoma (CTCL)
Efficacy and Safety of Naloxone Lotion for Treatment of Itchiness in Patients with Mycosis Fungoides (MF) Form of Cutaneous T-cell Lymphoma
Sponsor: Elorac, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ8604
U.S. Govt. ID: NCT02811783
Contact: Grace Ulerio: 2123056953 / gu2102@cumc.columbia.edu
Additional Study Information: This is a phase 2 study to determine the efficacy and safety of Naloxone HCL Lotion 0.5% for the treatment of mycosis fungoides (MF) type of cutaneous T-cell lymphoma (CTCL). Selected subjects will have the study drug applied to determine its effect on reducing itchiness and any potential side effects. Naloxone has previously been approved for direct blood administration for the treatment of narcotic overdose and has potential to treat the itchiness associated with MF. This is a 5 visit 6-9 week study involving blood collections and skin examinations performed in the clinic.
This study is closed
Larisa Geskin, MD
Do You Qualify?
Do you have mycosis fungoides (MF)? Yes No
Have you been experiencing daily ichiness for more than a month? Yes No
Can you follow treatment instructions and visits? Yes No
(Females only) Are you pregnant or nursing? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Grace Ulerio